Use of prescribed and non-prescribed medication for dyspepsia

Scandinavian Journal of Primary Health Care

Volumn 22, Issue 3, 2004, Pages 163-167

  Krol, Nicole ^a   Muris, Jean W M ^b   Schattenberg, Geert ^a   Grol, Richard ^a   Wensing, Michel ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Dyspepsia; General practice; Medication use; Patient survey study

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; DRUG USE; DYSPEPSIA; FEMALE; GENERAL PRACTITIONER; HEALTH EDUCATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION;

ADULT; DRUG UTILIZATION; DYSPEPSIA; FAMILY PRACTICE; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; QUESTIONNAIRES; SELF ADMINISTRATION; SELF MEDICATION;

EID: 2042417704     PISSN: 02813432     EISSN: None     Source Type: Journal    
DOI: 10.1080/02813430410006495     Document Type: Article

References (26)

1. Krol N, Spies TH, van Balen J, Hartman J, Wensing M, Grol R. Managing dyspepsia in general practice; an observational study. Quality in Primary Care 2003;11:173-80.
2. Bodger K, Daly MJ, Heatley RV. Prescribing patterns for dyspepsia in primary care: a prospective study of selected general practitioners. Aliment Pharmacol Ther 1996;10:889-95.
3. Stichting farmaceutische kengetallen. Omzet top 10 geneesmiddelen. 2000, Data en Feiten Selectie. Den Haag, 2001.
4. Quartero AO, Smeets HM, de Wit NJ. Trends and determinants of pharmacotherapy for dyspepsia: analysis of 3-year prescription data in The Netherlands. Scand J Gastroenterol 2003;38:676-7.
5. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998;317:452-6.
6. Grime J, Pollock K, Blenkinsopp A. Proton pump inhibitors: perspectives of patients and their GPs. Br J Gen Pract 2001;51:703-11.
7. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-3.
8. Hungin AP, Rubin GP, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463-4.
9. Pollock K, Grime J. Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self regulation of treatment may be an under-exploited resource. Soc Sci Med 2000;51:1827-39.
10. Numans ME, de Wit NJ, Geerdes RHM, Muris JWM, Starmans R, Postema PhJ, et al. NHG-Standaard Maagklachten (eerste herziening) [Dutch College of General Practitioners Guideline Dyspepsia, first revision]. Huisarts Wet 1996;39:565-77.
11. Numans ME, De Wit NJ, Dirven JAM, Hurenkamp GJB, Meijer QCM, Muris JWM, et al. NHG-standaard Maagklachten (tweede herziening) [Dutch College of General Practitioners Guideline Dyspepsia, second revision]. Huisarts Wet 2003;46:690-700.
12. Hunt RH. Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use [editorial]. CMAJ 1996;154:49-53.
13. Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001;345:810-6.
14. Stevenson A, Barry CA, Britten N, Barber N, Bradley CP. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med 2000;50:829-40.
15. Makoul G, Arntson P, Schofield T. Health promotion in primary care: physician-patient communication and decision making about prescription medications. Soc Sci Med 1995;41:1241-54.
16. Krol N, Weijnen CF, Numans ME, Wensing M, Grol R. General practitioners reflect on treatment of patients with dyspepsia; a qualitative interview study. Submitted 2004.
17. Van der Kuy A, red. Farmacotherapeutisch Kompas 2000/ 2001. Amstelveen: College voor Zorgverzekeringen, commissie farmaceutische hulp, 2000.
18. Veldhuyzen-van-Zanten SJ, Tytgat KM, Pollak PT, Goldie J, Goodacre RL, Riddell RH, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993;46:273-9.
19. Zee KI vd, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36: Een handleiding. [Measurement of general health with the RAND-36: A manual]. 1st ed. Groningen: Noordelijk Centrum voor Gezondheidsvraagstukken, 1993.
20. Shaw MJ, Fendrick AM, Kane RL, Adlis SA, Talley NJ. Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists. Am J Gastroenterol 2001;96:673-6.
21. Sihvo S, Hemminki E. Self-medication of dyspepsia: How appropriate is it? Scand J Gastroenterol 1997;32:855-61.
22. Kalish SC, Bohn RL, Avorn J. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use. Med Care 1997;35:32-48.
23. Dent J, Brun A, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl 2):S1-S16.
24. Scottish Intercollegiate Guidelines Network (SIGN). Dyspepsia. A national clinical guideline. Publication no. 68. Edinburgh: SIGN, 2003.
25. Hurenkamp GJ, Grundmeijer HG, Bindels PJ, Tytgat GN, van der Hulst RW. Chronisch gebruik van maagzuursecretieremmende medicatie in de huisartsenpraktijk in de regio Amsterdam [Chronic use of stomach acid inhibitor medication in family practice in the region of Amsterdam]. Ned Tijdsch Geneeskd 1999;143:410-3.
26. Barry CA, Bradley CP, Britten N, Stevenson A, Barber N. Patients' unvoiced agenda in general practice consultations: qualitative study. BMJ 2000;320:1246-50.